AKT1 and acute myeloid leukemia: The association of PIK3CA, AKT1, and mTOR with the overall survival of 106 AML patients (53 patients with high expression and 53 patients with low expression) is depicted in Fig. 2D–F through survival analysis using the GEPIA2 database.